AF9 targets acetyl-modified STAT6 to diminish purine metabolism and accelerate cell apoptosis during metastasis

Shao, Jianhua; Shi, Tiezhu; Chen, Lianheng; Wang, Shu; Yu, Hua; Feng, Nan; Wang, X.

doi:10.1038/s41418-023-01172-7

Cited by 1 publication

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately 50–90% of human proteins, including various tumor proteins and tumor suppressors, undergo PTM (Ray et al 2015 ). For instance, STAT6 acetylation can inhibit the migration and invasion of KIRC cells and contribute to the survival of KIRC patients (Shao et al 2023 ). S-palmitoylation, a reversible form of PTM, can modify protein secretion, transport, and interaction, and membrane trafficking and stability (Wu et al 2021a , b ).…”

Section: Introductionmentioning

confidence: 99%

zDHHC3-mediated S-palmitoylation of SLC9A2 regulates apoptosis in kidney clear cell carcinoma

Zhang,

Hou,

Zhou

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose Kidney clear cell carcinoma (KIRC) has a poor prognosis, high morbidity and mortality rates, and high invasion and metastasis rate, and effective therapeutic targets are lacking. zDHHC3 has been implicated in various cancers, but its specific role in KIRC remains unclear. Methods In this study, we performed a pan-cancer analysis, bioinformatics analysis, and cell experiment to detect the role of zDHHC3 in KIRC. Results zDHHC3 was significantly down-regulated in KIRC, and that its high expression was associated with favorable patient outcomes. We identified 202 hub genes that were most relevant to high zDHHC3 expression and KIRC, and found that they were involved mainly in ion transport and renal cell carcinoma. Among these hub genes, SLC9A2 was identified as a downstream gene of zDHHC3. zDHHC3 suppression led to decreased expression and S-palmitoylation of SLC9A2, which further inhibited the apoptosis of Caki-2 cells. Conclusion Our findings suggest that zDHHC3 plays an important role in KIRC, due partly to its regulation of SLC9A2 S-palmitoylation. The targeting of the zDHHC3–SLC9A2 axis may provide a new option for the clinical treatment of KIRC.

show abstract